299982_GeoVaxLogo.jpg
GeoVax Awarded NIH Fast Track Phase I/II Grant to Advance Lassa Fever Vaccine
April 10, 2018 09:00 ET | GeoVax, Inc.
Deadly epidemic continues in Nigeria; Lassa virus remains endemic in West Africa ATLANTA, GA, April 10, 2018 (GLOBE NEWSWIRE) -- GeoVax Labs, Inc. (OTCQB: GOVX), a biotechnology company developing...
299982_GeoVaxLogo.jpg
GeoVax Recognized as “Best Biotech” at Vaccine Industry Excellence Awards during World Vaccine Congress
April 05, 2018 09:00 ET | GeoVax, Inc.
ATLANTA, GA, April 05, 2018 (GLOBE NEWSWIRE) -- GeoVax Labs, Inc. (OTCQB: GOVX), a biotechnology company developing human vaccines, is honored to announce that it won “Best Biotech” at the World...
GeoVax.png
GeoVax Provides Vaccine Development Update
March 28, 2018 09:00 ET | GeoVax, Inc.
ATLANTA, GA, March 28, 2018 (GLOBE NEWSWIRE) -- GeoVax Labs, Inc. (OTCQB: GOVX), a biotechnology company developing innovative human vaccines using its novel platform technology, today...
GeoVax.png
GeoVax’s Chief Scientific Officer to Speak at World Vaccine Congress
March 26, 2018 09:00 ET | GeoVax, Inc.
GeoVax Also Nominated for Vaccine Industry Excellence Awards Atlanta, GA, March 26, 2018 (GLOBE NEWSWIRE) -- GeoVax Labs, Inc. (OTCQB: GOVX), a biotechnology company developing human vaccines,...
GeoVax.png
GeoVax Reports 2017 Year-End Financial Results
March 23, 2018 15:00 ET | GeoVax, Inc.
ATLANTA, March 23, 2018 (GLOBE NEWSWIRE) -- GeoVax Labs, Inc. (OTCQB:GOVX), a biotechnology company developing innovative human vaccines using its novel platform technology, today announced its...
GeoVax.png
GeoVax and CaroGen to Collaborate On Development of Therapeutic Hepatitis B Vaccine
February 07, 2018 09:00 ET | GeoVax, Inc.
Targeting Chronic Hepatitis B Infections Affecting More Than 240 Million People Worldwide ATLANTA, GA, Feb. 07, 2018 (GLOBE NEWSWIRE) -- GeoVax Labs, Inc. (OTCQB: GOVX), a biotechnology company...
GeoVax.png
GeoVax to Present at the 2018 ASM Biothreats Conference
January 31, 2018 09:00 ET | GeoVax, Inc.
ATLANTA, GA, Jan. 31, 2018 (GLOBE NEWSWIRE) -- GeoVax Labs, Inc. (OTCQB: GOVX), a biotechnology company developing human vaccines, announced that its Chief Scientific Officer, Farshad...
GeoVax.png
GeoVax Publishes Ebola Vaccine Study Results in Nature’s Scientific Reports
January 16, 2018 09:00 ET | GeoVax, Inc.
ATLANTA, GA, Jan. 16, 2018 (GLOBE NEWSWIRE) -- GeoVax Labs, Inc. (OTCQB: GOVX), a biotechnology company developing human vaccines, today announced publication of its manuscript entitled “A...
GeoVax.png
GeoVax and Vaxeal to Collaborate on Cancer Immunotherapy Program
January 03, 2018 09:00 ET | GeoVax, Inc.
ATLANTA, GA, Jan. 03, 2018 (GLOBE NEWSWIRE) -- GeoVax Labs, Inc. (OTCQB: GOVX), a biotechnology company developing human vaccines, announced today that it is collaborating with Vaxeal Holding SA on...
GeoVax.png
GeoVax to Present During China Showcase at Biotech Showcase 2018
January 02, 2018 12:00 ET | GeoVax, Inc.
Part of Larger Corporate Partnering Effort During the J.P. Morgan 36th Annual Healthcare Conference ATLANTA, GA, Jan. 02, 2018 (GLOBE NEWSWIRE) --  GeoVax Labs, Inc. (OTCQB: GOVX), a...